BOARD OF DIRECTORS

Philippe J. Goix, Ph.D.
President and Chief Executive Officer, Singulex, Inc.
Philippe Goix has more than a decade of entrepreneurial biotechnology experience, successfully leading fast growing, product-centered, innovative companies backed by institutional venture capitalists. Since joining Singulex in September 2004, Dr. Goix has driven Singulex technology toward commercialization, secured strategic intellectual property for its technology, raised several “up rounds” of funding, and built a strong reagent and diagnostics commercialization strategy.

Prior to joining Singulex, Philippe Goix founded Guava Technologies, Inc., where he held successive positions as president and chief technology officer. Dr. Goix founded Guava in June 1997 and led the company as it established a presence in the life science market. Under his leadership, Guava assembled industry-leading executives, raised capital to develop its proprietary technology, defined a strategy to commercialization, and identified a very strong demand for future products in the life science marketplace. Guava Technologies currently has over 1,200 systems in the field. Prior to this experience, Dr. Goix worked for more than 15 years in the field of laser analytical devices applied to fluid mechanics. He worked at CNRS in France, as a charge de recherché, at Sandia National Laboratories, and at Stanford University as a scientist, where he developed sophisticated laser-based diagnostic tools to investigate complex fluidics systems. Dr. Goix holds a doctorate in physics from University of Rouen, France and an MBA from the University of San Francisco.

Heiner Dreismann, Ph.D.
Heiner Dreismann has over 20 years’ experience in biotech and healthcare companies, most recently as president and CEO of Roche Molecular Systems, Inc. (RMS), the division of Hoffmann-La Roche Ltd that pioneered clinical molecular diagnostics. Before this, he held various management positions in Roche, among them head of integration office diagnostics for the merger of the IVD business of Roche Diagnostics and Boehringer Mannheim. Dr. Dreismann received his M.A. in biology and his Ph.D. in microbiology/molecular biology both from Westfalische Wilheims University in Munster, Germany.

Carl L. Gordon, Ph.D., CFA
General Partner of OrbiMed and Co-Head of Private Equity
Carl L. Gordon is a founding General Partner of OrbiMed and Co-Head of Private Equity. Mr. Gordon is active in both private equity and small-capitalization public equity investments. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Mr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors degree from Harvard College.

Gregory R. Johnson, Ph.D.
Director, Prolog Ventures, LLC
Gregory R. Johnson is a founder and managing director of Prolog Ventures. He brings more than two decades of experience in venture capital and 14 years as a general partner at Gateway Associates, a St. Louis-based venture capital company, to the board. Previously, he was Vice President of Monsanto Venture Capital and Monsanto’s Director of New Ventures and Technology. He oversaw Monsanto's $80 million portfolio of corporate venture capital investments, helped create its international network of funds, and worked on commercialization of technology developed at Washington University School of Medicine and Oxford University. He holds a doctoral degree in physics from the University of Rochester and a bachelor's degree from MIT.

Andre Marion, Ph.D.
Mr. Marion is a highly regarded entrepreneur and industry expert who brings over 25 years of management and commercialization experience in the life science industry. Mr. Marion was a founder of Applied Biosystems, Inc. (ABI), which has become one of the world's leading suppliers of instruments for the biotechnology research market. Dr. Marion was President, CEO, and Chairman at the time of ABI's merger with Perkin Elmer Corporation in 1993. He retired as President of the ABI division of PE Corp. in 1995. Prior to founding ABI, Dr. Marion held several research and development managerial positions at Hewlett-Packard Corporation.

Stephen L. Rose, CMA
Director, Fisk Ventures, LLC
Stephen L. Rose, CMA serves as Managing Director of Fisk Ventures, LLC, the venture investment company for H. Fisk Johnson, Ph.D., the Chairman and CEO of S.C. Johnson and Son Inc. In this capacity, Mr. Rose serves on the boards of several early-stage, technology-based companies, and has over 10 years of experience in venture investing. Formerly, over a 10-year period with S.C. Johnson, both in the US and in Canada, he held several positions, including strategic planning, new business, and new product development, along with financial and business management. Steve has an Honors Bachelor of Commerce from McMaster University and is also a Certified Management Accountant (CMA).

Mickey S. Urdea, Ph.D.
Founder, Chairman and Chief Executive Officer, Tethys Bioscience
Dr. Urdea was the head of the Nucleic Acid Diagnostics business unit at Chiron. In 1998, he joined Bayer Diagnostics as Senior Vice President of Nucleic Acid Diagnostics and acting-Chief Scientific Officer of Bayer Diagnostics. He left Bayer in 2000 and co-founded Tethys Bioscience in 2002. Dr. Urdea received a Ph.D. in biochemistry at Washington State University and held an NIH postdoctoral fellowship at UCSF with William J. Rutter. He has published more than 185 articles and book chapters, and is an inventor on more than 100 issued and pending patents.

Fred K. Vogt
Chairman of the Board, FKV Enterprises, LLC
Fred Vogt operated in several key manufacturing and operations positions with Mallinckrodt Group Inc. This included serving as president of Mallinckrodt Baker, a $300 million division providing laboratory and pharmaceutical chemicals. He later held the position of Senior Vice President within Tetra Technologies, Inc., a specialty chemical supplier.